Narlumosbartmab plus chemo for bone cancers with giant cells
Part of Bones, joints & muscles, Cancer clinical trials.
This trial tests a new drug called Narlumosbartmab added to standard chemotherapy for certain types of bone cancer that have eaten away at the bone and contain large, abnormal cells. It is for people who have not yet started standard treatment and whose tumors can be removed with surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 8 years old.
- You have a specific type of bone cancer (high-grade osteosarcoma, Ewing sarcoma, malignant giant cell tumor, or undifferentiated pleomorphic sarcoma) that has been confirmed by biopsy and includes multinucleated giant cells.
- You have not yet received standard treatment for this cancer, and you plan to have surgery at the study center.
- You are in good enough health to walk and care for yourself (ECOG score 0 or 1), and your doctor expects you to live more than 6 months.
- Your blood counts, liver, and kidney function are within acceptable ranges as shown on recent blood tests.
- You have no active jaw or dental problems, and you are not taking or planning to take certain bone medications or other cancer treatments during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental medication (JMT103) for people with giant cell tumor of bone that cannot be safely removed with surgery. The drug may help shrink the tumor or slow its growth, providing an option when surgery is too risky.
This trial tests a new combination of drugs and radiation to improve the effects of first-line chemotherapy and immunotherapy for patients with advanced non-small cell lung cancer that has spread to the bones. The goal is to help shrink tumors and potentially improve overall outcomes.
This trial tests a new drug, nelmastobart, combined with the chemotherapy docetaxel, for people with advanced non-small cell lung cancer that has a high level of a protein called BTN1A1. It is for patients who have already tried other treatments and are looking for a new option.
This trial compares a new drug called narlumosbart with denosumab (already used to treat bone problems) for people with multiple myeloma that has spread to the bone. The goal is to see if the new drug is as safe and effective at preventing bone complications.
This trial tests whether adding immunotherapy (a treatment that helps your immune system fight cancer) to chemotherapy can help young people whose bone or soft tissue sarcoma has come back or hasn't responded to previous treatment.
This study tests whether adding an investigational drug called BOLD-100 to a standard chemotherapy (doxorubicin) helps people with certain types of advanced soft tissue sarcoma. It might slow tumor growth or shrink tumors.
Hear when a new Malignant Bone Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.